Nikord is a groundbreaking NK cells developed from cord blood-derived NK cells. These cells can be efficiently expanded and stored in large quantities within an allogeneic biobank.

These cells is currently being evaluated in protocol-defined studies targeting various types of cancer, as well as in exploratory programs focused on neurodegenerative diseases. Each study outlines specific eligibility criteria, endpoints, and assessment methods. The product achieves over 90% NK cell purity after just 14 days of culture, positioning it as a highly efficient therapeutic option.

Nikord remains under active research and development for use in preclinical models.